Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh‐Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, et al.
Biological Psychiatry (2017) Vol. 84, Iss. 6, pp. 422-432
Closed Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Stefano Aringhieri, Marco Carli, Shivakumar Kolachalam, et al.
Pharmacology & Therapeutics (2018) Vol. 192, pp. 20-41
Closed Access | Times Cited: 177
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Tien-Wei Yu, Hsien‐Yuan Lane, Chieh‐Hsin Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8208-8208
Open Access | Times Cited: 128
Sodium Benzoate—Harmfulness and Potential Use in Therapies for Disorders Related to the Nervous System: A Review
Łucja Justyna Walczak-Nowicka, Mariola Herbet
Nutrients (2022) Vol. 14, Iss. 7, pp. 1497-1497
Open Access | Times Cited: 87
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
Holger Rosenbrock, Michael Desch, Glen Wunderlich
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1557-1566
Open Access | Times Cited: 46
Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders
Noemi Nicosia, M. Giovenzana, Paulina Misztak, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6521-6521
Open Access | Times Cited: 20
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 18
Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials
Myeongju Cho, Tae Young Lee, Yoo Bin Kwak, et al.
Australian & New Zealand Journal of Psychiatry (2019) Vol. 53, Iss. 8, pp. 742-759
Open Access | Times Cited: 113
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, et al.
CNS Spectrums (2019) Vol. 24, Iss. S1, pp. 38-69
Open Access | Times Cited: 104
Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia
Michel Cuénod, Pascal Steullet, Jan-Harry Cabungcal, et al.
Molecular Psychiatry (2021) Vol. 27, Iss. 4, pp. 1886-1897
Open Access | Times Cited: 80
Glutamatergic dysfunction in Schizophrenia
Andreas O. Kruse, Juan Bustillo
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 66
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 52
d-Amino acids: new clinical pathways for brain diseases
Isis Nem de Oliveira Souza, Robin Roychaudhuri, Jacqueline de Belleroche, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 12, pp. 1014-1028
Open Access | Times Cited: 28
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23
Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat
Ryan T. Terry-Lorenzo, Ruicheng Fan, Ni A. Khin, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review
Ragy R. Girgis, Anthony W. Zoghbi, Daniel C. Javitt, et al.
Journal of Psychiatric Research (2018) Vol. 108, pp. 57-83
Closed Access | Times Cited: 68
Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress
Chieh‐Hsin Lin, Hsien‐Yuan Lane
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 64
d-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders
Herman Wolosker, Darrick T. Balu
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 54
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Felipe V. Gomes, Anthony A. Grace
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4467-4467
Open Access | Times Cited: 45
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia
Chieh‐Hsin Lin, Ping-Kun Chen, Shi‐Heng Wang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216156-e216156
Open Access | Times Cited: 43
Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial
Chieh‐Hsin Lin, Shi‐Heng Wang, Hsien‐Yuan Lane
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 7, pp. 545-555
Open Access | Times Cited: 32
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
Andrea de Bartolomeis, Licia Vellucci, Mark C. Austin, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 909-909
Open Access | Times Cited: 30
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 7
Astrocytic Regulation of Glutamate Transmission in Schizophrenia
Yu-Ying Mei, Dong Wu, Ning Zhou
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top